DocMorris AG

ROSE

CH0042615283

Drug Retailers

Market Closed - Swiss Exchange Other stock markets 16:30:02 17/05/2024 BST			5-day change	1st Jan Change
70 ^CHF	-4.37%		-6.10%	-5.08%

05-16	DOCMORRIS : Sell rating from UBS	ZD
04-23	DOCMORRIS : Deutsche Bank remains its Buy rating	ZD

Zur Rose Group AG Provides Earnings Guidance for the Year 2021

March 18, 2021 at 01:00 pm

Zur Rose Group AG provided earnings guidance for the year 2021. For the period, the company expects sales growth of around 20%, including Medpex and Apotal. Revenue expects to grow to above CHF 4 billion.

Latest news about DocMorris AG

DOCMORRIS : Sell rating from UBS	05-16	ZD
DOCMORRIS : Deutsche Bank remains its Buy rating	04-23	ZD
DOCMORRIS : Hauck & Aufhauser gives a Buy rating	04-19	ZD
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	04-18
DOCMORRIS : Gets a Buy rating from Warburg Research	04-18	ZD
DOCMORRIS : Receives a Buy rating from Berenberg	04-18	ZD
DOCMORRIS : Gets a Buy rating from Baader Bank	04-17	ZD
DOCMORRIS : Deutsche Bank gives a Buy rating	04-17	ZD
DOCMORRIS : Warburg Research reiterates its Buy rating	04-16	ZD
DOCMORRIS : UBS reaffirms its Sell rating	04-16	ZD
DOCMORRIS : Gets a Buy rating from Jefferies	04-16	ZD
Swiss online drug delivery firm DocMorris reports slight miss in Q1 sales	04-16	RE
DOCMORRIS : Jefferies keeps its Buy rating	04-12	ZD
DOCMORRIS : Hauck & Aufhauser raises its recommendation to Buy	04-12	ZD
DOCMORRIS : Deutsche Bank reaffirms its Buy rating	04-11	ZD
DOCMORRIS : Receives a Buy rating from Jefferies	04-10	ZD
DOCMORRIS : Baader Bank reaffirms its Buy rating	04-10	ZD
DOCMORRIS : Warburg Research keeps its Buy rating	04-10	ZD
DOCMORRIS : UBS reaffirms its Sell rating	04-02	ZD
DOCMORRIS : Baader Bank maintains a Buy rating	03-26	ZD
DOCMORRIS : Deutsche Bank keeps its Buy rating	03-22	ZD
DOCMORRIS : Buy rating from Warburg Research	03-22	ZD
DOCMORRIS : Receives a Buy rating from Warburg Research	03-21	ZD
DOCMORRIS : Baader Bank remains its Buy rating	03-21	ZD
Transcript : DocMorris AG, 2023 Earnings Call, Mar 21, 2024	03-21

Chart DocMorris AG

Duration

Period

More charts

Company Profile

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Sector

Drug Retailers

Calendar

28/05/2024 - UBS Swiss Day

More about the company

Income Statement Evolution

More financial data

Ratings for DocMorris AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

70 CHF

Average target price

99.24 CHF

Spread / Average Target

+41.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
DOCMORRIS AG	-5.08%	963M
WALGREENS BOOTS ALLIANCE, INC.	-30.37%	15.68B
JD HEALTH INTERNATIONAL INC.	-20.84%	12.39B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-22.17%	6.74B
MATSUKIYOCOCOKARA & CO.	-6.15%	6.29B
YIFENG PHARMACY CHAIN CO., LTD.	+11.76%	6.26B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+70.00%	4.95B
NAHDI MEDICAL COMPANY	-1.90%	4.66B
CLICKS GROUP LIMITED	-5.58%	4.03B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-7.87%	3.62B

Other Drug Retailers

DocMorris AG

Equities

ROSE

CH0042615283

Drug Retailers

Zur Rose Group AG Provides Earnings Guidance for the Year 2021

EPS Revisions